|1.||Chuck, Roy S: 3 articles (02/2007 - 01/2007)|
|2.||Lekhanont, Kaevalin: 3 articles (02/2007 - 01/2007)|
|3.||Brashear, A: 3 articles (12/2006 - 01/2001)|
|4.||Halem, Monica: 3 articles (05/2005 - 05/2003)|
|5.||Baumann, Leslie: 3 articles (05/2005 - 05/2003)|
|6.||Slezinger, Anele: 3 articles (05/2005 - 05/2003)|
|7.||Vujevich, Justin: 3 articles (05/2005 - 05/2003)|
|8.||Black, Laura: 3 articles (05/2005 - 05/2003)|
|9.||Bryde, Joy: 3 articles (05/2005 - 05/2003)|
|10.||Lowe, Nicholas J: 2 articles (12/2014 - 03/2002)|
08/01/2003 - "Patients with MPS who received BTX-A reported significantly greater reductions in pain for longer durations compared with those who received BTX-B. "
08/01/2003 - "Patients who received BTX-A had significantly greater mean reductions in VAS pain scores compared with those who received BTX-B (mean reduction, 2.7 vs 1.8, respectively; P < 0.001). "
12/01/2001 - "In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. "
04/01/2012 - "Residual limb pain improved 3 months after intracutaneous, low-dose BTX-B in a trial with 9 patients and also phantom pain by tendency. "
09/01/2015 - "Two months after LSB with BTX-B, pain intensity and the Leeds assessment of neuropathic symptoms and signs (LANSS) score were significantly reduced. "
10/01/2014 - "In this prospective, uncontrolled study Btx B seems to be both a safe and effective treatment in craniofacial hyperhidrosis improving quality of life and reducing extreme sweating."
03/01/2005 - "There are sparse data, however, in the literature evaluating the safety and efficacy of BTX-B for the treatment of palmar hyperhidrosis. "
10/01/2014 - "To evaluate the safety and clinical effect of Btx B in craniofacial hyperhidrosis. "
01/01/2004 - "This chapter will review what is currently known about BTX-B and its current use in regards to the treatment of hyperhidrosis."
01/01/2004 - "This past year researchers have been investigating the efficacy as well as defining the dosing and application regiments of BTX-B in the treatment of hyperhidrosis. "
04/01/2003 - "BTX-B was approved for use in cervical dystonia in 2000, but it has been used off-label to treat facial wrinkles as reported in several open-label studies. "
01/01/2001 - "A study in patients who continued to respond to BTX-A and a similarly designed study in patients who were resistant to BTX-A demonstrated statistical improvement in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in those treated with BTX-B (evaluated as NeuroBloc) compared with placebo. "
09/13/2005 - "To compare autonomic effects of botulinum toxin (BTX), we randomized patients with cervical dystonia to receive either BTX-A or BTX-B in a double-blind manner. "
07/01/2005 - "Botulinum toxin type B (BTX-B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. "
05/01/2005 - "Botulinum toxin type B (BTX-B, Myobloc, San Francisco, CA, USA) was FDA-approved for the treatment of cervical dystonia in December 2000. "
01/01/2013 - "Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. "
01/01/2013 - "Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. "
01/01/2013 - "Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study. "
01/01/2013 - "To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. "
10/01/2011 - "Although findings from this study suggest that BTX-B was ineffective in treatment of facial flushing, it is significant that, to the best of our knowledge, this is the first report on an investigator-initiated, randomized, split-face trial for evaluation of efficacy of BTX-B treatment for facial flushing."
10/01/2011 - "We evaluated the efficacy of BTX-B for improvement of facial flushing. "
10/01/2011 - "No studies have been conducted to date for evaluation of the effect of botulinum toxin type B (BTX-B) on facial flushing. "
|2.||Botulinum Toxins (Botulinum Toxin)
|4.||Ophthalmic Solutions (Eye Drops)
|7.||Sodium Channels (Sodium Channel)